Short Interest in CalciMedica Inc. (NASDAQ:CALC) Drops By 38.9%

CalciMedica Inc. (NASDAQ:CALC) was the recipient of a significant drop in short interest in February. As of February 13th, there was short interest totaling 427,832 shares, a drop of 38.9% from the January 29th total of 699,828 shares. Approximately 5.1% of the company’s stock are sold short. Based on an average daily volume of 811,614 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily volume of 811,614 shares, the days-to-cover ratio is presently 0.5 days. Approximately 5.1% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Sound View Wealth Advisors Group LLC bought a new position in CalciMedica in the 2nd quarter valued at about $32,000. Cetera Investment Advisers boosted its holdings in shares of CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after acquiring an additional 9,045 shares during the period. Atria Investments Inc grew its position in shares of CalciMedica by 20.0% in the second quarter. Atria Investments Inc now owns 44,700 shares of the company’s stock valued at $72,000 after purchasing an additional 7,436 shares during the last quarter. Jane Street Group LLC bought a new position in shares of CalciMedica during the fourth quarter worth approximately $127,000. Finally, Envestnet Asset Management Inc. lifted its holdings in CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after purchasing an additional 34,386 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CALC. Wall Street Zen raised CalciMedica to a “sell” rating in a report on Saturday, January 17th. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Thursday, January 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CalciMedica in a research note on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $16.00.

CalciMedica Trading Down 6.5%

Shares of CalciMedica stock opened at $0.52 on Friday. The company has a debt-to-equity ratio of 1.39, a current ratio of 4.03 and a quick ratio of 4.04. The business has a fifty day simple moving average of $3.42 and a two-hundred day simple moving average of $3.40. CalciMedica has a 1 year low of $0.50 and a 1 year high of $7.20. The company has a market capitalization of $7.44 million, a price-to-earnings ratio of -0.32 and a beta of 0.49.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.